Abstract:Highlights • Synergistic Immune Activation: The sustained release of CDDP and DAC triggers Gasdermin E (GSDME)-mediated pyroptosis, which activates the adaptive immune response, while Mn 2+ enhances the activation of innate immunity through the STING pathway. • Significant Anti-Tumor Effects: The immunogel has shown encouraging anti-tumor effects, with an 80 % total survival rate for recurrent tumors and a 60 % survival rate for metastatic tumors. • Simplicity in Formulation and Preparation: The formulation of the immunogel is simple, and the preparation method is easy to handle, offering a promising strategy for postoperative cancer therapy. Tumor recurrence and metastasis after surgery are important factors affecting patient survival. The immunosuppressed tumor microenvironment after surgery reduces the ability of the immune system to clear residual tumor cells, thus increasing the risk of recurrence and metastasis. Currently, immunotherapy-based adjuvant therapy can effectively inhibit tumor recurrence and metastasis after surgery, but simultaneous and efficient synergistic activation of adaptive and innate immunity is a challenge. Here, we utilized polymeric hydrogel loaded with decitabine (DAC), cisplatin (CDDP) and manganese ions (Mn 2+ ) as a postoperative filler immunogel to synergistically activate both anti-tumor innate and adaptive immunity. The sustained release of CDDP and DAC burst gasdermin E (GSDME)-mediated pyroptosis and activated adaptive immunity, while Mn 2+ enhanced intrinsic immune activation through STING pathway. Such immunogel achieved an encouraging anti-tumor effect with an 80 % total survival rate for recurrent tumors and a 60 % survival rate for metastatic tumors. Considering that this in situ immunogel possesses simple formulation and displays superior anti-tumor effect, this research provided a promising strategy for postoperative cancer therapy. Graphical abstract After surgery, a suppressed immune system increases the risk of tumor recurrence and metastasis. The novel immunogel in our study, a polymer hydrogel with pyroptosis inducers and adjuvants, works synergistically to enhance anti-tumor immunity and achieve survival rates of 80 % for recurrence and 60 % for metastasis. Download: Download high-res image (411KB) Download: Download full-size image

Injectable Hydrogel-Based Tumor Vaccine with Fibrotic Tumor Immune Microenvironment Remodeling to Prevent Breast Cancer Postoperative Recurrence and Metastases

Injectable Zwitterionic Physical Hydrogel with Enhanced Chemodynamic Therapy and Tumor Microenvironment Remodeling Properties for Synergistic Anticancer Therapy

A Cancer Vaccine-Mediated Postoperative Immunotherapy for Recurrent and Metastatic Tumors.

Promoting The Recruitment, Engagement, And Reinvigoration of Effector T Cells via An Injectable Hydrogel with A Supramolecular Binding Capability for Cancer Immunotherapy

Injectable Polydopamine Nanoparticle-Incorporated Hydrogels for Antiangiogenesis and Stimulating Tumoricidal Immunity to Inhibit Metastasis and Recurrence Postresection

Antigenicity and adjuvanticity co-reinforced personalized cell vaccines based on self-adjuvanted hydrogel for post-surgical cancer vaccination

Injectable Liquid Crystal Formation System for Reshaping Tumor Immunosuppressive Microenvironment to Boost Antitumor Immunity: Postoperative Chemoimmunotherapy

Combination of GNRs-PEI/cGAMP-laden Macrophages-Based Photothermal Induced in Situ Tumor Vaccines and Immune Checkpoint Blockade for Synergistic Anti-Tumor Immunotherapy.

Bifunctional Fusion Membrane‐Based Hydrogel Enhances Antitumor Potency of Autologous Cancer Vaccines by Activating Dendritic Cells

Biomimetic Hydrogel‐Mediated Mechano‐Immunometabolic Therapy for Inhibition of ccRCC Recurrence After Surgery

An Ultrasound‐Responsive and In Situ Gelling Hydrogel Nanocomposite for Boosting Anti PD‐L1 Immunotherapy via Remodeling Aberrant ECM of Post‐Surgical Residual Cancer

Injectable microenvironment-responsive hydrogels with redox-activatable supramolecular prodrugs mediate ferroptosis-immunotherapy for postoperative tumor treatment

Macrophage-derived implantable vaccine prevents postsurgical tumor recurrence

Polymeric immunogel prevents tumor recurrence and metastasis by dual activation of innate and adaptive immunity

A Novel Octa-Arginine-Modified Injectable Self-Assembling Peptide Hydrogel for Multidrug-Resistant Cancer Therapy

Injectable Adhesive Hydrogel as Photothermal‐Derived Antigen Reservoir for Enhanced Anti‐Tumor Immunity

A single-shot prophylactic tumor vaccine enabled by an injectable biomembrane hydrogel

Interventional hydrogel microsphere vaccine as an immune amplifier for activated antitumour immunity after ablation therapy

Unified Therapeutic‐Prophylactic Vaccine Demonstrated with a Postoperative Filler Gel to Prevent Tumor Recurrence and Metastasis

An Adhesive Immune‐Stimulating Multifunctional Hydrogel for Potent Tumor Chemoimmunotherapy and Postoperative Wound Healing Promotion

An adhesive hydrogel implant combining chemotherapy and tumor microenvironment remodeling for preventing postoperative recurrence and metastasis of breast cancer